Skip to main content
. 2020 Jul 24;105(10):e3730–e3741. doi: 10.1210/clinem/dgaa478

Figure 3.

Figure 3.

Change in height SD from mean baseline HtSDS (∆HtSDS) during GH therapy (GHT) in GH-deficient childhood cancer survivors at 1 and 5 years of GHT, according to tumor subgroup. SDS, SD score.